Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human Study
Authors:
- Kyoung Soo LimKLKyoung Soo Lim
- Min Kyu ParkMPMin Kyu Park
- Seo-Hyun YoonSYSeo-Hyun Yoon
- Joo-Youn ChoJoo-Youn Cho
- Sang-Goo ShinSSSang-Goo Shin
- In-Jin JangIJIn-Jin Jang
- Kyung-Sang YuKYKyung-Sang Yu
- 1 September 2012
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 34 (9) , 1986-1998
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetesLife Sciences, 2012
- A review of gliptins in 2011Expert Opinion on Pharmacotherapy, 2011
- The DPP‐4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic dosesBritish Journal of Clinical Pharmacology, 2011
- Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetesBioorganic & Medicinal Chemistry Letters, 2011
- Pharmacokinetics of dipeptidylpeptidase‐4 inhibitorsDiabetes, Obesity and Metabolism, 2010
- A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy SubjectsThe Journal of Clinical Pharmacology, 2009
- DPP-4 inhibitorsBest Practice & Research Clinical Endocrinology & Metabolism, 2007
- QT Interval: How to Measure It and What Is “Normal”Journal of Cardiovascular Electrophysiology, 2006
- Global Prevalence of DiabetesDiabetes Care, 2004
- Confidence Interval Criteria for Assessment of Dose ProportionalityPharmaceutical Research, 2000